Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients with Myocardial Infarction and No-reflow

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

May 31, 2024

Study Completion Date

December 31, 2025

Conditions

Acute Myocardial Infarction

Interventions

DRUG

Glycoprotein IIb/IIIa inhibitors

Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy

Trial Locations (1)

University of Luebeck, Lübeck

All Listed Sponsors

lead

University of Luebeck

OTHER